The allowance of a patent for Namodenoson in Canada represents a significant step forward for Can-Fite BioPharma in securing its intellectual property rights and potentially expanding its market reach. This development could lead to increased investor confidence and a positive outlook on the company's future revenue streams, thus potentially driving up the stock price in the short term.